Navigation Links
Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
Date:4/23/2009

LOS ANGELES (April 23, 2009) The Food and Drug Administration (FDA) gave its approval this week for Emmaus Medical, Inc. to begin a Phase 3 clinical trial of an experimental treatment for sickle cell disease. The patented experimental treatment was originally developed by investigators led by Yutaka Niihara, MD, MPH, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and is licensed to Emmaus Medical.

The patented drug treatment involves the oral administration of L-glutamine, which is the most common amino acid in the body. This is one of a very few experimental treatments for sickle cell disease to reach the Phase 3 clinical trial stage.

"News of this clinical trial should be of great interest to the millions of people around the world who suffer from painful crises caused by sickle cell disease," said Dr. Niihara. "Phase 3 clinical trials are large, randomized studies conducted at multiple sites to determine the safety and efficacy of a potential treatment. Phase 3 clinical trials are usually the last clinical trials conducted before FDA approval is obtained and the treatment can be made widely available to the patient population."

Sickle cell disease is an inherited disorder that causes red blood cells to become oxidized, sticky and sickle shaped instead of smooth, pliable and round. Sickle cell disease leads to anemia, organ damage, chronic and acute pain and a host of other problems.

"In our Phase 2 clinical trial, we observed an excellent safety profile and positive trends in reducing the number of crises and hospitalizations in sickle cell disease patients," said Dr. Niihara. "We look forward to initiating the Phase 3 clinical trial and remain committed to developing a treatment for sickle cell disease."


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert  

Page: 1

Related medicine news :

1. Anticlotting drug found to be safe in sickle cell patients
2. New Kind of Stem Cells Reverse Sickle Cell Anemia
3. Children with sickle cell disease, silent strokes show some relief with blood transfusions
4. Sickle Cell Disease Pain Can Occur Daily and Is Much More Severe Than Previously Thought
5. Sickle Cell Patients in More Pain Than Thought
6. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
7. For children with sickle cell disease, lung disease is part of the package
8. Lung Trouble Associated With Sickle Cell in Kids
9. Researchers Develop Stem Line With Sickle Cell Mutation
10. Effective treatment for sickle cell underused by doctors
11. Sickle Cell Drug Underused by Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and light leaks to your ... clip to clip with high quality 4K lens flare footage," said Christina Austin - ... flares filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare 4K Jewel lens ...
(Date:12/5/2016)... , ... December 05, 2016 , ... What: Shriners Hospitals ... the North Pole to our patients – using a video monitor and web-enabled camera. ... hospital will transform the Auditorium into a Christmas Wonderland, which is where the video ...
(Date:12/5/2016)... ... 05, 2016 , ... Edward Buckingham MD , and ... of the newest Sciton laser in January 2017. The Halo is the first ... ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically ...
(Date:12/5/2016)... ... , ... For many years, Andrew G. Zubinas has accumulated over ... of the Lithuanian language and its poetry inspired him in writing “ ... explores all aspects of a living, breathing forest where nothing ever stays the same. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted from December 5, ... Central Awards. , Awards include the Information Security Executive® of the Year, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology: